Pharmacokinetics and metabolism of intravenous midazolam in preterm infants

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 6, 2001, Pages 525-531

  De Wildt, S N ^a   Kearns, G L ^b   Hop, W C J ^b   Murry, D J ^b   Abdel Rahman, S M ^b   Van Den Anker, J N ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXYMIDAZOLAM; CYTOCHROME P450 3A4; DRUG METABOLITE; INDOMETACIN; MIDAZOLAM; MIDAZOLAM MALEATE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GAS CHROMATOGRAPHY; HEMODYNAMICS; HUMAN; KIDNEY FUNCTION; MALE; MASS SPECTROMETRY; NEWBORN; NEWBORN INTENSIVE CARE; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL;

ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; GESTATIONAL AGE; HALF-LIFE; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM;

EID: 0035652107     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.120683     Document Type: Article

References (24)

1. Premedication before intubation in UK neonatal units
2. Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies
3. Population pharmacokinetics of midazolam in neonates
4. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
5. Inhibitory anti-CYP3A4 pepdde antibody: Mapping of inhibitory epitope and specificity toward other CYP3A isoforms
6. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
7. Cytochrome P450 3A: Ontogeny and drug disposition
8. Expression of CYP3A in the liver. Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
9. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers
10. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: Midazolam neonatal pharmacokinetics
11. The pharmacokinetics of midazolam in paediatric patients
12. The pharmacokinetics of midazolam in man
13. Pharmacokinetics of midazolam in critically ill neonates
14. Steady-state plasma concentrations of midazolam in critically ill infants and children
15. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery
16. Midazolam: Pharmacology and uses
17. Failure of critically ill patients to metabolise midazolam
18. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: Synergistic increase of CYP3A4 induction by pregnane X receptor activators
19. Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients
20. Drug disposition in neonates with patent ductus arteriosus
21. Ceftazidime pharmacokinetics in preterm infants: Effect of postnatal age and postnatal exposure to indomethacin
22. Measurement by HPLC of midazolam and its major metabolite, 1-hydroxymidazolam in plasma of very premature neonates
23. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates
24. Infusion of midazolam in paediatric patients after cardiac surgery